(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
01 December 2022 (01.12.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/250499 A1

(51) International Patent Classification:
A61K 9/08 (2006.01) *A61K 47/38* (2006.01)
A61K 9/10 (2006.01) *A61K 9/00* (2006.01)
A61K 47/10 (2006.01) *A61K 31/41* (2006.01)
A61K 47/02 (2006.01) *A61P 25/00* (2006.01)
A61K 47/36 (2006.01)

(21) International Application Number:
PCT/KR2022/007581

(22) International Filing Date:
27 May 2022 (27.05.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/194,276 28 May 2021 (28.05.2021) US

(71) Applicant: **SK BIOPHARMACEUTICALS CO., LTD.** [KR/KR]; 221, Pangyoyeok-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 13494 (KR).

(72) Inventors: **PENDSE, Pravada**; 673 Skyline Drive, Lake Hopatcong, New Jersey 07849 (US). **BOMMANA, Murali M**; 2 Liberty Way, Monroe TWP, New Jersey 08831 (US). **NOH, Regina H.**; 90 Prospect Ave. 3A, Hackensack, New Jersey 07601 (US). **PEGAN, Augustin**; 11 Stoneleigh Terrace, Riverdale, New Jersey 07457 (US). **WEBB, Travis John**; 3600 68th st N, St Petersburg, Florida 33710 (US). **MAXWELL, Jejuan**; 1741 West Manor Ave., Clearwater, Florida 33765 (US).


(74) Agent: **HANSUNG INTELLECTUAL PROPERTY**; Halla Classic Building 4F. 23 Gangnam-daero 84-gil, Gangnam-gu, Seoul 06233 (KR).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(54) Title: ORAL AQUEOUS SUSPENSION FORMULATIONS COMPRISING CARBAMATE COMPOUND



(A: 10 min, B: 5hr, C: 24hr; Left to right: 0.10, 0.50, 1.00, and 1.50 mg/mL poloxamer 188)

(57) Abstract: The present disclosure relates to an aqueous formulation comprising as an active ingredient a carbamate compound of Formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof, poloxamer, and an aqueous carrier, wherein the aqueous formulation is in the form of a suspension formulation.

WO 2022/250499 A1